Table 4.
Top 5 HD markers in the striatum of Q175 altered by the TRF treatment
| Comparison | Q175 vs WT | Ad lib vs TRF | ||||
|---|---|---|---|---|---|---|
| Age | 2 months | 6 months o | 10 months | 9 months | ||
| Gene Symbol | Full name | Log2 fold change | Log2 fold change | p value | ||
| Striatum | ||||||
| Fos | FBJ osteosarcoma oncogene | ns | ↓ | ns | ↑ | 0.0004 |
| Htr2a* | 5-Hydroxytryptamine (serotonin) receptor 2A | ns | ns | ns | ↑ | 0.0005 |
| Hrh3 | Histamine receptor H3 | ns | ↓ | ↓ | ↑ | 0.0009 |
| Chrm4 | Cholinergic receptor, muscarinic 4 | ↓ | ↓ | ↓ | ↑ | 0.0012 |
| Tacr1 | Tachykinin receptor 1 | ns | ↓ | ↓ | ↑ | 0.0020 |
P value of the t test comparison with Q175 housed under ad lib is shown. Asterisk indicates HD markers changed in both the striatum and cortex. Transcripts increased by the treatment (Log2 fold change) are shown in green (↑) and those decreased by the treatment in red (↓). Transcripts without significant change (p > 0.05) are shown in gray (ns); 24% gene expressions in the striatum and 7% gene expressions in the cortex are altered by the TRF treatment. Among altered genes in striatum, >50% genes (13/24) that are shown downregulated in Q175 controls (comparison with age-matched WT controls (Lengfelder et al., 2016) are upregulated by TRF.